Robert Applegate

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
    J Am Coll Cardiol 40:78-83. 2002
  2. ncbi request reprint PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 18:604-13. 2006
  3. ncbi request reprint Drug-eluting stents versus bare metal stents in ST elevation myocardial infarction: from evidence to practice
    N D Noureddine
    Wake Forest School of Medicine, Section of Cardiology, Winston Salem, NC, USA
    Minerva Cardioangiol 60:1-9. 2012
  4. doi request reprint Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents
    Robert J Applegate
    Wake Forest School of Medicine, Winston Salem, NC 27157 1045, USA
    EuroIntervention 7:1030-42. 2012
  5. doi request reprint Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007
    Robert J Applegate
    Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
    JACC Cardiovasc Interv 1:317-26. 2008
  6. ncbi request reprint Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention using thrombin hemostatic patch-facilitated manual compression
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 19:164-70. 2007
  7. ncbi request reprint Vascular complications in women after catheterization and percutaneous coronary intervention 1998-2005
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 19:369-74. 2007
  8. ncbi request reprint Culprit vessel PCI versus traditional cath and PCI for STEMI
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC, 27157 1045, USA
    J Invasive Cardiol 20:224-8. 2008
  9. doi request reprint "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
    J Am Coll Cardiol 51:607-14. 2008
  10. doi request reprint Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, North Carolina 27157 1045, USA
    Catheter Cardiovasc Interv 72:7-12. 2008

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
    J Am Coll Cardiol 40:78-83. 2002
    ..The study assessed clinical outcomes of closure device use following percutaneous coronary revascularization using current standards of anticoagulation and antiplatelet therapy...
  2. ncbi request reprint PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 18:604-13. 2006
    ..Whether abciximab can be used safely or effectively during PCI for high-risk patients after upstream treatment with eptifibatide in patients with acute coronary syndromes (ACS) is not known...
  3. ncbi request reprint Drug-eluting stents versus bare metal stents in ST elevation myocardial infarction: from evidence to practice
    N D Noureddine
    Wake Forest School of Medicine, Section of Cardiology, Winston Salem, NC, USA
    Minerva Cardioangiol 60:1-9. 2012
    ..We will consider the evidence that evaluates the relative safety and efficacy of DES compared to BMS in STEMI patients, as well as address practical issues faced in the routine clinical care of these patients...
  4. doi request reprint Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents
    Robert J Applegate
    Wake Forest School of Medicine, Winston Salem, NC 27157 1045, USA
    EuroIntervention 7:1030-42. 2012
    ..To evaluate whether the improved outcomes with newer generation drug-eluting stents (DES) utilising thin-strut stents are consistent among different patient and angiographic subgroups...
  5. doi request reprint Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007
    Robert J Applegate
    Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
    JACC Cardiovasc Interv 1:317-26. 2008
    ..This study sought to evaluate trends in vascular complications after diagnostic cardiac catheterization (CATH) and percutaneous coronary intervention (PCI) from the femoral artery from 1998 to 2007...
  6. ncbi request reprint Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention using thrombin hemostatic patch-facilitated manual compression
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 19:164-70. 2007
    ..To evaluate the adjusted risk of vascular complications after thrombin hemostasis patch-facilitated manual compression (THP-MC) for femoral artery access site management...
  7. ncbi request reprint Vascular complications in women after catheterization and percutaneous coronary intervention 1998-2005
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 19:369-74. 2007
    ..Whether awareness of this gender risk or implementation of strategies to reduce the overall incidence of vascular complications has had an effect on the incidence of vascular complications in women is unknown...
  8. ncbi request reprint Culprit vessel PCI versus traditional cath and PCI for STEMI
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC, 27157 1045, USA
    J Invasive Cardiol 20:224-8. 2008
    ....
  9. doi request reprint "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
    J Am Coll Cardiol 51:607-14. 2008
    ..The aim was to compare 2-year outcomes with the routine use of drug-eluting stents (DES) (>75% "off-label") with a comparable group treated with bare-metal stents (BMS)...
  10. doi request reprint Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, North Carolina 27157 1045, USA
    Catheter Cardiovasc Interv 72:7-12. 2008
    ..To compare late outcomes with the routine use of drug-eluting stents (DES) compared with bare-metal stents (BMS) during percutaneous intervention (PCI) of saphenous vein grafts (SVGs)...
  11. doi request reprint Incidence of coronary stent thrombosis based on academic research consortium definitions
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Am J Cardiol 102:683-8. 2008
    ..Use of the ARC probable stent thrombosis paralleled rates of definite stent thrombosis alone, but partially masked the occurrence of late (>1 year) stent thrombosis in DESs compared with BMSs...
  12. doi request reprint Treatment of ostial lesions using the Szabo technique: a case series
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC, USA
    Catheter Cardiovasc Interv 72:823-8. 2008
    ..We discuss relevant technical issues using this technique as well as potential advantages and disadvantages...
  13. doi request reprint Prognostic implications of vascular complications following PCI
    Robert Applegate
    Wake Forest School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston Salem, North Carolina, USA
    Catheter Cardiovasc Interv 74:64-73. 2009
    ..To evaluate the effect of vascular complications (VC) on the adjusted risk of nonfatal myocardial infarction (MI) or death following percutaneous coronary intervention (PCI) at 1 year in a large contemporary cohort...
  14. doi request reprint 3-year comparison of drug-eluting versus bare-metal stents
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, North Carolina 27157 1045, USA
    JACC Cardiovasc Interv 2:231-9. 2009
    ....
  15. doi request reprint Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC 27157 1045, USA
    Circ Cardiovasc Interv 2:35-42. 2009
    ..Drug-eluting stents (DES) may reduce this effect in select patients; however, whether this benefit occurs in high-risk lesions and patients in routine practice is not clear...
  16. doi request reprint Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial
    Robert Applegate
    Wake Forrest University School of Medicine, Winston Salem, NC, USA
    Catheter Cardiovasc Interv 76:644-51. 2010
    ..To evaluate whether an everolimus-eluting stent (EES) with thinner stent struts and polymer results in less periprocedural myonecrosis and adverse outcomes...
  17. doi request reprint Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial
    Robert J Applegate
    Wake Forest University Health Sciences, Winston Salem, NC, USA
    EuroIntervention 6:437-46. 2010
    ..To examine the two year clinical outcomes in dual-vessel disease from the SPIRIT III trial comparing the XIENCE V(r) everolimus-eluting stent (EES) to the TAXUS Express2(tm) paclitaxel-eluting stent (PES)...
  18. doi request reprint Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial)
    Robert J Applegate
    Wake Forest University Health Sciences, Winston Salem, NC, USA
    Am J Cardiol 107:833-40. 2011
    ..From 1 year to 3 years hazard curves continued to diverge in favor of EES, consistent with an improving long-term safety and efficacy profile of EES compared to PES, with no evidence of late catchup...
  19. ncbi request reprint Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and death
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Am J Cardiol 99:333-8. 2007
    ....
  20. ncbi request reprint Restick following initial Angioseal use
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Catheter Cardiovasc Interv 58:181-4. 2003
    ..There were no major bleeding, vascular repair, vessel occlusion, or embolizations. Three large hematomas (1.7%) were noted. These data suggest that restick can be performed safely after initial Angioseal deployment...
  21. ncbi request reprint The Angio-Seal Evolution registry: outcomes of a novel automated Angio-Seal vascular closure device
    Robert J Applegate
    Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 22:420-6. 2010
    ....
  22. ncbi request reprint Restenosis of a sirolimus drug-eluting stent: aorto-ostial involvement of the proximal right coronary artery
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Catheter Cardiovasc Interv 67:391-5. 2006
    ..We discuss issues relevant to management of the restenotic drug-eluting stent in the aorto-ostial location...
  23. ncbi request reprint Vascular complications with newer generations of angioseal vascular closure devices
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
    J Interv Cardiol 19:67-74. 2006
    ..To evaluate the safety and efficacy of newer generations of a single vascular closure device (VCD), Angioseal, compared to contemporaneous manual compression...
  24. ncbi request reprint Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention 1998-2003
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
    Catheter Cardiovasc Interv 67:556-62. 2006
    ..To evaluate the adjusted risk of vascular complications after manual compression and vascular closure devices for femoral artery access site management in a large contemporary cohort, using propensity score analysis...
  25. ncbi request reprint Bivalirudin and DES: a PCI strategy that pays
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    J Invasive Cardiol 19:69-70. 2007
  26. doi request reprint Transitioning to the radial artery as the preferred access site for cardiac catheterization: an academic medical center experience
    Samuel Turner
    Section of Cardiology, Wake Forest School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina, USA
    Catheter Cardiovasc Interv 80:247-57. 2012
    ....
  27. ncbi request reprint Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomes
    Kevin R Hayes
    Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 22:266-70. 2010
    ..We sought to examine the clinical presentations and subsequent clinical outcomes of patients undergoing target lesion revascularization (TLR) after either bare-metal stent (BMS) or drug-eluting stent (DES) placement...
  28. ncbi request reprint Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions
    Efthymios N Deliargyris
    Cardiology Section, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 16:611-6. 2004
    ..Both abciximab (AB) and eptifibatide (EP) are approved for use during percutaneous coronary intervention (PCI) but comparative data between the 2 agents are limited...
  29. ncbi request reprint Automated contrast injection in contemporary practice during cardiac catheterization and PCI: effects on contrast-induced nephropathy
    Jason Call
    Winchester Cardiology and Internal Medicine, Inc, Winston Salem, North Carolina, USA
    J Invasive Cardiol 18:469-74. 2006
    ....
  30. ncbi request reprint Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts
    Bharathi Upadhya
    Cardiology Section, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Am J Cardiol 96:515-8. 2005
    ..3% vs 72.4%; odds ratio 3.7; 95% confidence interval 2.2 to 6.3). Thus, an elevated preprocedural WBC count is associated with increased risk of MACEs in patients undergoing PCI for saphenous vein graft lesions...
  31. ncbi request reprint Safety of abciximab administration during PCI of patients with previous stroke
    Efthymios N Deliargyris
    Cardiology Section, Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
    J Thromb Thrombolysis 19:147-53. 2005
    ..To examine the frequency of cerebrovascular complications among patients receiving abciximab (AB) undergoing PCI with prior intracranial hemorrhage (ICH) or recent (< 2 years) ischemic strokes...
  32. ncbi request reprint Late outcomes after intervention of vein grafts in diabetics with abciximab use
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
    Int J Cardiol 111:136-41. 2006
    ..We sought to evaluate late clinical outcomes following elective percutaneous coronary interventions for saphenous vein graft with planned abciximab use in diabetics...
  33. ncbi request reprint Differences in baseline characteristics and in-hospital outcomes in patients with or without prior stroke undergoing percutaneous coronary intervention
    Bharathi Upadhya
    Cardiology Section, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC, 27157 1045, USA
    J Invasive Cardiol 17:243-7. 2005
    ..A prior stroke may identify patients who have a higher risk for post-PCI complications. However, no comparative data exist on post-PCI outcomes of patients with or without prior stroke...
  34. ncbi request reprint Treatment of complex LAD-diagonal bifurcation disease using paclitaxel drug-eluting stents
    Robert J Applegate
    Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
    J Invasive Cardiol 17:390-2. 2005
  35. doi request reprint Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction
    Nathan D Lambert
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
    Am Heart J 157:688-94. 2009
    ..Whether moderate CKD and proteinuria increase the risk of ST after MI is not known. This study evaluated the risk of ST associated with moderate CKD and dipstick proteinuria...
  36. ncbi request reprint Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention
    Scott A McKee
    Wake Forest University School of Medicine, Winston Salem, NC, USA
    Am Heart J 154:159-64. 2007
    ..We postulated that cocaine use would be associated with increased risk for stent thrombosis...
  37. doi request reprint Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stenting
    Terry R Ketch
    Cardiology Section, Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
    Am Heart J 156:234-40. 2008
    ..We determined whether PTDF predicts events in patients with MI and compared this assay with brain natriuretic peptide (BNP) and C-reactive protein (CRP)...
  38. doi request reprint ABO blood types: influence on infarct size, procedural characteristics and prognosis
    Terry R Ketch
    Cardiology Section, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
    Thromb Res 123:200-5. 2008
    ..However, the effect of blood group status on size of MI, procedural findings and outcomes after PCI for MI have not been reported...
  39. ncbi request reprint Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction
    James G Jollis
    Department of Cardiology, Duke University, Durham, North Carolina, USA
    JAMA 298:2371-80. 2007
    ..Despite 2 decades of evidence demonstrating benefits from prompt coronary reperfusion, registries continue to show that many patients with ST-segment elevation myocardial infarction (STEMI) are treated too slowly or not at all...
  40. ncbi request reprint Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel
    J Emilio Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Catheter Cardiovasc Interv 64:369-72. 2005
    ..While minor and major TIMI bleeding remained very low in both groups, CD was associated with a twofold increase in risk of any-bleeding event when compared to MC, especially when using GP IIb/IIIa inhibitors...
  41. ncbi request reprint Vascular closure devices: the second decade
    Harold L Dauerman
    Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
    J Am Coll Cardiol 50:1617-26. 2007
    ..Challenges in the second decade of VCD experience will include performing definitive randomized trials, evaluating outcomes in higher-risk patients, and developing more ideal closure devices...
  42. ncbi request reprint Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 48:2440-7. 2006
    ..This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES)...
  43. ncbi request reprint A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study
    David J Moliterno
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 42:1132-9. 2003
    ..Morrisville, North Carolina), a new point-of-care test...
  44. ncbi request reprint Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels
    Jacqueline Saw
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Thromb Res 112:301-6. 2003
    ..A new point-of-care device, Rapidpoint ENOX, was recently developed to measure clotting times with enoxaparin use...